{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:55:15Z","timestamp":1773442515743,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cmi.2024.03.037","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T12:58:37Z","timestamp":1712408317000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","author":[{"given":"Connor","family":"Prosty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Katergi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne Bou","family":"Rjeily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Butler-Laporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.03.037_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00101-22","article-title":"Pneumocystis jirovecii pneumonia in people living with HIV: a review","author":"McDonald","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2024.03.037_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3201\/eid1010.030985","article-title":"Current epidemiology of Pneumocystis pneumonia","volume":"10","author":"Morris","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/infdis\/jiw085","article-title":"Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000\u20132010","volume":"214","author":"Buchacz","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archinte.1996.00440020081010","article-title":"A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens","volume":"156","author":"Ioannidis","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005646.pub2","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2024.03.037_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042560-199706010-00002","article-title":"Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients","volume":"15","author":"Bucher","year":"1997","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol Off Publ Int Retrovirol Assoc"},{"key":"10.1016\/j.cmi.2024.03.037_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","year":"2023"},{"key":"10.1016\/j.cmi.2024.03.037_bib12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.03.037_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine","volume":"334","author":"Collier","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cmi.2024.03.037_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2024.03.037_bib16","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.03.037_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(98)07399-1","article-title":"Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, C\u00f4te d\u2019Ivoire: a randomised trial","volume":"353","author":"Anglaret","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.03.037_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/00002030-199512000-00007","article-title":"Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of pneumocystis carinii pneumonia and toxoplasmic encephalitis","volume":"9","author":"Antinori","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2024.03.037_bib19","first-page":"341","article-title":"Comparative trial of dapsone versus trimethoprim\/sulfamethoxazole for primary prophylaxis of pneumocystis carinii pneumonia","volume":"5","author":"Blum","year":"1992","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"10.1016\/j.cmi.2024.03.037_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection","volume":"332","author":"Bozzette","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","article-title":"Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides","volume":"180","author":"Chan","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib22","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.1988.03720080019021","article-title":"Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS","volume":"259","author":"Fischl","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.03.037_bib24","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM199305273282102","article-title":"Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against pneumocystis carinii pneumonia and toxoplasmosis in HIV infection","volume":"328","author":"Girard","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib25","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199212243272604","article-title":"A controlled trial of trimethoprim\u2013sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome","volume":"327","author":"Hardy","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","article-title":"A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia","volume":"324","author":"Hirschel","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00002030-199407000-00009","article-title":"Aerosolized pentamidine as primary prophylaxis for pneumocystis carinii pneumonia: efficacy, mortality and morbidity","volume":"8","author":"Lidman","year":"1994","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2024.03.037_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002030-199301000-00009","article-title":"Primary prophylaxis for pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine","volume":"7","author":"Mallolas","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2024.03.037_bib29","first-page":"457","article-title":"Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Francaise de Prevention des Maladies Infectieuses","volume":"7","author":"May","year":"1994","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"10.1016\/j.cmi.2024.03.037_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00126334-200102010-00004","article-title":"Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar","volume":"26","author":"Maynart","year":"2001","journal-title":"Senegal. J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2024.03.037_bib31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/0003-4819-114-11-948","article-title":"Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study","volume":"114","author":"Montaner","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/00365549509019012","article-title":"Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia in patients with AIDS","volume":"27","author":"Nielsen","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib33","first-page":"472","article-title":"Aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a controlled, randomized trial","volume":"6","author":"Jensen","year":"1993","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"10.1016\/j.cmi.2024.03.037_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/clinids\/20.3.531","article-title":"Once-weekly administration of dapsone\/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients","volume":"20","author":"Opravil","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0753-3322(97)82322-0","article-title":"A\u00a0controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS","volume":"51","author":"Payen","year":"1997","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.cmi.2024.03.037_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-122-10-199505150-00004","article-title":"Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and toxoplasmosis in patients infected with HIV","volume":"122","author":"Podzamczer","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002030-199304000-00008","article-title":"Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients","volume":"7","author":"Podzamczer","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2024.03.037_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0163-4453(95)92035-8","article-title":"Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group","volume":"31","author":"Rizzardi","year":"1995","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2024.03.037_bib39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/infdis\/172.3.656","article-title":"Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group","volume":"172","author":"Salmon-Ceron","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A controlled trial of aerosolized pentamidine or trimethoprim\u2013sulfamethoxazole as primary prophylaxis against pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection","volume":"327","author":"Schneider","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00002030-199210000-00017","article-title":"Oral dapsone versus nebulized pentamidine for pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity","volume":"6","author":"Slavin","year":"1992","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2024.03.037_bib42","first-page":"573","article-title":"Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis","volume":"95","author":"Torres","year":"1993","journal-title":"Contin Dev Nabumetone Investig Update"},{"key":"10.1016\/j.cmi.2024.03.037_bib43","author":"Besant-Jones"},{"key":"10.1016\/j.cmi.2024.03.037_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2024.03.037_bib45","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1093\/cid\/ciac645","article-title":"Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis: a systematic review and meta-analysis","volume":"76","author":"Prosty","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/520433","article-title":"A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons","volume":"29","author":"El-Sadr","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-dose tmp-smx in the treatment of pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib48","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/infdis\/171.6.1632","article-title":"Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group","volume":"171","author":"Schneider","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciy154","article-title":"Pneumocystis cytochrome b mutants associated with atovaquone prophylaxis failure as the cause of pneumocystis infection outbreak among heart transplant recipients","volume":"67","author":"Argy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.03.037_bib50","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.03.037_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13587","article-title":"Practice the AIDC of. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Fishman","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2024.03.037_bib52","first-page":"CD005590","article-title":"Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2024.03.037_bib53","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017","volume":"6","author":"Frank","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2400168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2400168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T06:11:16Z","timestamp":1715148676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2400168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S1198743X2400168X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.03.037","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}